Trending Topics in Gastroenterology | GastroAGI

Noninvasive Markers of Portal Hypertension and Varices in Noncirrhotic Disease

Noncirrhotic portal hypertension (NCPH) encompasses a range of disorders affecting the hepatic portosinusoidal vascular system, leading to portal hypertension (PH). Unlike cirrhosis, there are no established noninvasive criteria to diagnose PH or varices in NCPH. A study aimed to address this gap by evaluating noninvasive markers, including liver stiffness measurement (LSM) via transient elastography, platelet count, and imaging/laboratory data, to predict PH and varices. The study included patients with NCPH who underwent transjugular liver biopsy. PH was defined by the presence of varices on endoscopy, portosystemic collaterals, or ascites on imaging. Results indicated that LSM values were higher in patients with PH and varices, while platelet counts were significantly lower in these groups. A multivariate analysis combining LSM and platelet count demonstrated strong predictive ability for PH and varices, with high sensitivity, negative predictive value, and accuracy. A stepwise decision model incorporating platelet count and LSM was developed to noninvasively detect PH and varices. The model showed 100% sensitivity and negative predictive value for both PH and varices, with high overall accuracy. This suggests that combining LSM and platelet count could serve as a reliable, noninvasive method to identify NCPH patients at risk for PH and varices. However, further validation in independent cohorts is necessary to confirm its utility. In conclusion, this study highlights the potential of noninvasive markers as effective tools for diagnosing PH and varices in NCPH, reducing the need for invasive procedures like liver biopsy.

VanC-IT: A Phase 2 Randomized Trial of Oral Vancomycin in Primary Sclerosing Cholangitis

The VanC-IT trial is a phase 2 clinical study designed to evaluate the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis (PSC), a chronic and progressive liver disease for which no approved disease-modifying therapies currently exist. PSC is characterized by inflammation and scarring of the bile ducts, leading to cholestasis (impaired bile flow), liver damage, and eventually liver failure. Liver transplantation remains the only definitive treatment for PSC. Additionally, PSC is often associated with inflammatory bowel disease (IBD), though the disease can occur independently of IBD. ### Study Design: The VanC-IT trial is a **prospective, randomized, double-blind, placebo-controlled phase 2 study**, meaning participants are randomly assigned to either the treatment group (oral vancomycin) or the placebo group, and neither the participants nor the researchers know which treatment is being administered (double-blind design). This ensures unbiased assessment of the efficacy and safety of oral vancomycin. The trial is **conducted in Italy** and includes both adult and adolescent patients diagnosed with PSC, regardless of whether they have IBD. Eligible participants undergo a screening process and are stratified based on their baseline liver stiffness before randomization. This stratification ensures that differences in liver stiffness, which is a marker of liver disease severity, are accounted for during analysis. ### Rationale: The rationale for investigating oral vancomycin in PSC stems from emerging evidence that implicates the **gut–liver axis** and **microbiome alterations** in the pathogenesis of PSC. The gut–liver axis refers to the bidirectional relationship between the gastrointestinal tract and the liver, which is influenced by microbial populations in the gut. Alterations in the microbiome may play a role in driving inflammation and immune dysregulation seen in PSC. Oral vancomycin, an antibiotic, has been hypothesized to modulate the gut microbiome and reduce inflammation, making it a potential therapeutic option for PSC. ### Objectives: The trial aims to assess the impact of oral vancomycin on disease activity, with a focus on both efficacy and safety. The study is designed to generate high-quality evidence to inform future therapeutic strategies for PSC. #### Primary Outcome: The primary outcome of the VanC-IT trial is **changes in biochemical markers of cholestasis**, which reflect treatment response. These markers include measurements such as alkaline phosphatase (ALP), bilirubin levels, and other indicators of bile duct function. #### Secondary Outcomes: The secondary outcomes are more comprehensive and include: - Liver biochemistry (e.g., liver enzyme levels). - Disease risk scores (such as the Mayo Risk Score for PSC). - Imaging findings (e.g., changes in liver stiffness or bile duct abnormalities). - Circulating biomarkers related to inflammation and liver function. - Quality of life assessments (to evaluate the impact of treatment on patients' overall well-being). - PSC-related clinical events (e.g., episodes of cholangitis or disease progression). #### Exploratory Outcomes: An important exploratory component of the trial involves investigating treatment-related biological mechanisms, with a focus on: - **Gut microbiota analysis**: Understanding how oral vancomycin affects microbial populations in the gut. - **Metabolomic profiling**: Identifying changes in metabolic pathways that may be linked to treatment effects. - **Immunological markers**: Evaluating immune system changes and inflammatory responses related to treatment. ### Significance: The VanC-IT trial is expected to provide valuable insights into the role of oral vancomycin as a potential therapy for PSC. By rigorously evaluating its efficacy and safety, the trial aims to address the unmet need for disease-modifying treatments in PSC. Additionally, the study’s exploratory analyses may shed light on microbiome-related pathways and mechanisms underlying PSC, which could guide the development of future therapeutic strategies. ### Expected Outcomes: The findings from the VanC-IT trial are anticipated to: 1. Inform the design of larger, definitive clinical trials in PSC management. 2. Provide evidence on the utility of microbiome-targeted therapies in PSC. 3. Improve understanding of the gut–liver axis and its role in PSC pathogenesis. In summary, the VanC-IT trial represents a critical step toward developing effective treatments for PSC, a disease with limited therapeutic options. By investigating oral vancomycin, the study aims to address the urgent need for evidence-based therapies while expanding knowledge of PSC-related biological mechanisms.

Spironolactone, Eplerenone and Ascites

Spironolactone and Eplerenone are both mineralocorticoid receptor antagonists (MRAs) that are commonly used in the management of conditions such as heart failure, hypertension, and ascites due to liver cirrhosis. Ascites is the abnormal accumulation of fluid in the abdominal cavity, often resulting from liver cirrhosis and portal hypertension. Below is a detailed explanation of their role in managing ascites, their comparative efficacy, and side effect profiles: --- ### **Role in Ascites Management** - **Spironolactone**: - Spironolactone is a potassium-sparing diuretic that blocks aldosterone receptors. Aldosterone promotes sodium and water retention, and its antagonism by spironolactone facilitates the excretion of sodium and water, helping to reduce fluid accumulation in ascites. - It is considered the first-line therapy for ascites due to liver cirrhosis, often in combination with a salt-restricted diet. - **Eplerenone**: - Like spironolactone, eplerenone is also an aldosterone antagonist, but it is a more selective agent. Eplerenone has a lower affinity for androgen and progesterone receptors compared to spironolactone, which reduces its risk of hormonal side effects. - Eplerenone is increasingly being studied as an alternative to spironolactone for managing ascites, especially in patients who are intolerant to spironolactone's side effects. --- ### **Comparison of Efficacy** - Both spironolactone and eplerenone are effective in reducing fluid retention in ascites caused by liver cirrhosis. - In the study cited, spironolactone (100 mg) and eplerenone (100 mg) demonstrated similar efficacy in terms of weight reduction and abdominal girth measurements. This indicates that both drugs are comparable in their ability to manage ascites effectively. - However, eplerenone at a lower dose (50 mg) was found to be less effective compared to spironolactone and eplerenone at 100 mg. --- ### **Side Effect Profiles** - **Spironolactone**: - **Gynecomastia and Mastalgia**: Spironolactone has significant anti-androgenic properties, which can lead to gynecomastia (breast enlargement in men) and mastalgia (breast pain). In the study, 14.28% of patients on spironolactone developed gynecomastia. - **Hyperkalemia**: There is a small risk of hyperkalemia (elevated potassium levels), which was observed in 2.8% of patients in the study. - **Eplerenone**: - Eplerenone has a much lower affinity for androgen and progesterone receptors, which significantly reduces the risk of hormonal side effects such as gynecomastia and mastalgia. In the study, no cases of gynecomastia or mastalgia were reported in patients treated with eplerenone. - Hyperkalemia was not observed in patients treated with eplerenone in the study, although it remains a potential risk with this class of drugs. --- ### **Why is Eplerenone Needed?** Eplerenone is required as an alternative to spironolactone for patients who experience intolerable side effects, particularly gynecomastia and mastalgia, which are common with spironolactone. Its more selective action on aldosterone receptors without significant interaction with androgen or progesterone receptors makes it a better-tolerated option for many patients. --- ### **Conclusion** - Both spironolactone and eplerenone are effective in managing ascites due to liver cirrhosis. However, eplerenone has a superior side effect profile, making it a more favorable option for patients who cannot tolerate the hormonal side effects of spironolactone. - The choice between the two drugs should be individualized based on patient tolerance, side effect profile, and clinical circumstances. - Further studies may be warranted to explore the long-term efficacy and safety of eplerenone in this patient population. In summary, while spironolactone remains a cornerstone in the treatment of ascites, eplerenone is emerging as a valuable alternative with fewer side effects, particularly for patients who are sensitive to spironolactone's hormonal effects.

Plasma Volume expansion in cirrhosis - J of Hepatology - Jan.26

### **Introduction** Plasma volume expansion is a critical therapeutic strategy in the management of acute kidney injury (AKI) in patients with cirrhosis and ascites. AKI in cirrhosis often arises due to hypovolemia, which is frequently exacerbated by diuretic therapy, systemic vasodilation, and circulatory dysfunction inherent to advanced liver disease. The primary goal of plasma volume expansion is to restore effective circulating volume, improve renal perfusion, and mitigate kidney injury. Traditionally, therapeutic protocols have favored a fixed duration of plasma volume expansion, most commonly extending to forty-eight hours. However, evolving evidence and expert consensus have challenged this uniform approach, advocating for more individualized strategies tailored to patient response. --- ### **Problem Statement** Despite its central role in AKI management, plasma volume expansion presents several challenges: 1. **Duration of Therapy**: While a forty-eight-hour expansion period has historically been favored, recent discussions suggest shorter durations may suffice in certain cases. However, abbreviated protocols risk misclassifying AKI severity and prematurely discontinuing therapy in patients who may benefit from extended volume support. 2. **Adverse Effects**: Over-administration of fluids in non-responders can lead to complications, such as fluid overload, pulmonary edema, and worsening ascites. Conversely, insufficient resuscitation may fail to address hypovolemia, prolonging kidney injury and worsening outcomes. 3. **Lack of Standardized Criteria**: There is no universally accepted protocol regarding the type of fluid (e.g., albumin versus crystalloids), dosing, or criteria for assessing response. This lack of standardization complicates clinical decision-making and may lead to inconsistent practices across healthcare settings. 4. **Identification of Non-Responders**: Prolonged plasma volume expansion may be unnecessary in patients who fail to show early improvement, underscoring the importance of identifying non-responders and adapting therapy accordingly. These challenges highlight the need for a more nuanced approach to plasma volume expansion, emphasizing individualized treatment strategies based on early assessment of therapeutic response. --- ### **Conclusion** Plasma volume expansion remains a cornerstone of AKI management in cirrhosis and ascites, but its application requires careful consideration to balance benefits against potential harms. While extending therapy to forty-eight hours may improve diagnostic accuracy in selected patients, it is vital to monitor response closely and reconsider prolonged fluid administration in non-responders. An individualized approach—guided by early assessment of therapeutic efficacy—offers the best opportunity to optimize outcomes while minimizing complications. Future research should focus on defining standardized criteria for fluid type, dose, duration, and response evaluation to refine plasma volume expansion strategies further.

Evolving diagnosis of HRS - J of Hepatology - Jan.26

The evolving diagnosis of hepatorenal syndrome–acute kidney injury (HRS-AKI) has been a significant topic of discussion in hepatology, nephrology, and critical care, particularly as newer insights challenge traditional diagnostic protocols. Historically, the diagnosis of HRS-AKI has relied heavily on rigid protocols, such as mandatory administration of albumin over a fixed period and adherence to absolute serum creatinine thresholds. These approaches were developed during a time when the understanding of acute kidney injury (AKI) in cirrhosis was relatively limited. However, advances in medical research and clinical care have revealed the complexities of AKI in cirrhosis, including dynamic physiological changes, overlapping mechanisms of kidney injury, and the need for more nuanced, multidisciplinary approaches. ### Problem Statement: The traditional diagnostic framework for HRS-AKI presents several challenges: 1. **Rigid Protocols:** Mandatory empiric albumin administration and fixed serum creatinine thresholds may not account for the diverse phenotypes of kidney injury in cirrhosis. This approach risks misclassification, delays in appropriate therapy, and unnecessary harm to patients who may be euvolemic or volume overloaded. 2. **Overlooking Complexity:** Dichotomizing HRS-AKI and acute tubular necrosis fails to acknowledge diagnostic uncertainty and the overlapping pathophysiology of these conditions. 3. **Disadvantaged Populations:** The reliance on absolute creatinine cutoffs disproportionately affects vulnerable populations, including women, older adults, and individuals with sarcopenia. 4. **Limited Multidisciplinary Input:** Excluding key specialties like nephrology and critical care from guideline development restricts the ability to address the full spectrum of AKI in cirrhosis. ### Conclusion: A protocol-driven approach to diagnosing HRS-AKI no longer aligns with the evolving understanding of kidney injury in cirrhosis. Evidence supports a shift towards precision-based care that emphasizes individualized clinical judgment, early reassessment of volume status, multidisciplinary collaboration, and physiologically guided fluid management. This transition aims to enable timelier diagnoses, more appropriate therapies, and reduced risks of preventable harm. Moving away from historical dogma and embracing personalized clinical decision-making represents a necessary evolution in the care of patients with cirrhosis and acute kidney injury. These advancements underscore the importance of adapting diagnostic frameworks to reflect current scientific knowledge and patient-centered care principles.

The GAVAPROSEC trial - J of Hepatology - Jan.26

The GAVAPROSEC trial provides critical randomized evidence addressing the management of acute gastric variceal bleeding (GVB) in patients with cirrhosis. Gastric variceal bleeding, particularly from fundal gastric varices (GOV2) or isolated gastric varices (IGV1), is a severe and life-threatening complication of portal hypertension, associated with high rebleeding rates and mortality. Despite guidelines recommending endoscopic glue injection for acute hemostasis, the optimal strategy for secondary prophylaxis has remained unclear due to limited robust evidence. The trial investigated the role of pre-emptive transjugular intrahepatic portosystemic shunt (TIPS) placement within 72 hours after stabilization in patients with acute gastric variceal bleeding. The results demonstrated that pre-emptive TIPS significantly improved rebleeding-free survival compared to standard strategies, which often involve glue obliteration combined with non-selective beta blockers. Importantly, the study found no increase in the incidence of hepatic encephalopathy, a common concern with TIPS procedures. Although no definitive overall survival benefit was observed, the high crossover rate to TIPS in the control group likely diluted the statistical power to detect a survival advantage. The findings of the GAVAPROSEC trial emphasize the limitations of glue-based strategies, which are associated with high rebleeding rates and depend on technical expertise that may not be uniformly available. By contrast, pre-emptive TIPS offers a more effective approach to secondary prophylaxis in this high-risk population. The trial's results support the consideration of pre-emptive TIPS as a first-line strategy after initial stabilization of gastric variceal bleeding, provided that patient selection and local expertise are carefully considered. In conclusion, the GAVAPROSEC trial represents a significant advancement in the management of acute gastric variceal bleeding. It provides strong evidence supporting the use of pre-emptive TIPS to improve clinical outcomes, particularly rebleeding-free survival, in a population with historically poor prognoses. This trial is likely to influence future guidelines and clinical practice, offering a more standardized approach to this challenging condition.

RIPK3 a novel biomarkers in cirrhosis - J of Hepatology - Jan.26

RIPK3 (Receptor-interacting protein kinase 3) is a crucial protein involved in necroptosis, a regulated form of cell death distinct from apoptosis. Necroptosis plays a significant role in inflammatory and degenerative diseases, including liver diseases such as cirrhosis, acute decompensation (AD), and acute-on-chronic liver failure (ACLF). RIPK3 is emerging as a novel biomarker in these conditions due to its strong association with disease severity, organ dysfunction, and mortality. ### Problem Statement: Patients with cirrhosis who experience acute decompensation (AD) or progress to acute-on-chronic liver failure (ACLF) frequently develop multi-organ failure and face high mortality rates. Current prognostic models for these patients often lack precision, particularly in identifying key drivers of disease progression. Non-apoptotic forms of cell death, such as necroptosis, have been implicated in the pathophysiology of AD and ACLF, but their contribution to organ failure and mortality has not been fully understood. RIPK3, a central mediator of necroptosis, has been identified as a potential biomarker for these conditions, offering an opportunity to improve risk stratification and guide therapeutic interventions. ### Conclusion: The study highlights RIPK3 as a key driver of organ failure and mortality in patients with AD and ACLF. Elevated plasma levels of RIPK3 were strongly associated with multi-organ dysfunction, particularly hepatic and renal failure, as well as disease progression and mortality. A mortality prediction model incorporating RIPK3 (>2.261x ULN), along with other clinical parameters like CLIF-C OF (Chronic Liver Failure Consortium Organ Failure score) and leukocytosis/leukopenia, demonstrated high accuracy in predicting outcomes. Furthermore, hepatic RIPK1 expression was found to be elevated in ACLF patients and correlated with disease severity and mortality, emphasizing the role of necroptosis originating in the liver. This study underscores the importance of RIPK3 as a biomarker for risk stratification in AD and ACLF. By integrating RIPK3 into predictive models, clinicians can enhance their ability to identify high-risk patients and personalize therapeutic strategies targeting necroptosis. This approach has the potential to revolutionize clinical decision-making and improve outcomes for patients with these life-threatening liver conditions.

INTEGRIS-PSC trial - J of Hepatology -Jan.26

The INTEGRIS-PSC trial, as described in the Journal of Hepatology on January 26, is a phase II clinical study investigating the safety, tolerability, and exploratory pharmacodynamics of **bexotegrast (PLN-74809)**, an oral, once-daily dual selective inhibitor of **αvβ6 and αvβ1 integrins**, in participants with **primary sclerosing cholangitis (PSC)** and liver fibrosis. Below is a detailed breakdown of the problem statement, the investigational drug, and the conclusions: ### **What is Bexotegrast?** Bexotegrast (PLN-74809) is a novel, oral, once-daily medication that selectively inhibits **αvβ6 and αvβ1 integrins**. These integrins play a critical role in activating transforming growth factor-β (TGF-β) signaling pathways, which are implicated in the development and progression of liver fibrosis. By targeting these integrins, bexotegrast aims to reduce the activation of TGF-β, thereby potentially halting or reversing liver fibrosis in conditions like PSC. ### **Problem Statement** Primary sclerosing cholangitis (PSC) is a rare, chronic, and progressive cholestatic liver disease of unknown etiology. It is characterized by inflammation and fibrosis of the bile ducts, leading to liver damage and, ultimately, liver failure. Currently, there are no approved therapies to effectively halt or reverse the progression of PSC. This creates an **urgent unmet medical need** for safe and effective treatments that can address the fibrosis and other pathological processes associated with PSC. ### **Study Design** The INTEGRIS-PSC trial was a **randomized, double-blind, dose-ranging phase II study** that enrolled 117 participants with PSC and suspected liver fibrosis. Participants were randomized to receive **bexotegrast** (at doses of 40 mg, 80 mg, 160 mg, or 320 mg) or placebo for varying durations (12 to 40 weeks). The primary endpoint was the incidence of treatment-emergent adverse events (TEAEs), while exploratory pharmacodynamic endpoints included biomarkers of fibrosis (e.g., ELF score, PRO-C3), liver stiffness measurements, and imaging parameters. ### **Key Findings** 1. **Safety and Tolerability**: - Bexotegrast was well tolerated across all dose levels (up to 320 mg daily for 40 weeks). - The incidence of treatment-emergent adverse events (TEAEs) was similar between the bexotegrast (72.7%) and placebo (70.0%) groups. - TEAEs were mild to moderate, with no serious adverse events attributed to the study drug. 2. **Pharmacodynamic Outcomes**: - Participants receiving bexotegrast showed **numerically less progression in exploratory pharmacodynamic markers** (e.g., ELF score, PRO-C3 levels, MRI-based liver assessments) compared to placebo at Week 12. - Improvements in MRI parameters continued through Week 24, indicating potential ongoing benefits of the drug. ### **Conclusion** The INTEGRIS-PSC trial demonstrated that **bexotegrast is safe and well tolerated** in participants with PSC and liver fibrosis, with no serious drug-related adverse events reported. Additionally, the drug was associated with **less progression in exploratory pharmacodynamic markers** of fibrosis and liver health compared to placebo. These findings support the hypothesis that targeting integrin-mediated TGF-β activation could be a promising therapeutic strategy for PSC. ### **Impact and Implications** This study provides early evidence for the safety and potential efficacy of bexotegrast in PSC, addressing a critical unmet need for therapies capable of halting or reversing the progression of this debilitating disease. Future studies are warranted to further evaluate the long-term efficacy and clinical benefits of bexotegrast in PSC.

ELMWOOD trial for PSC - J of Hepatology - Jan.26

The ELMWOOD trial, published in the Journal of Hepatology on January 26, focuses on evaluating the efficacy and safety of **Elafibranor**, a dual peroxisome proliferator-activated receptor-α/δ (PPAR-α/δ) agonist, in treating **primary sclerosing cholangitis (PSC)**. PSC is a rare, chronic liver disease characterized by progressive inflammation and scarring of the bile ducts, often leading to liver damage and complications such as cirrhosis. ### Problem Statement The trial aimed to address the lack of effective treatments for PSC, as current therapeutic options are limited. Specifically, the study investigated whether Elafibranor could provide biochemical and clinical improvements in patients with PSC, focusing on its impact on **alkaline phosphatase (ALP)** levels (a key marker of liver health) and **enhanced liver fibrosis (ELF) scores**, while also assessing its safety and tolerability compared to placebo. ### Conclusion The ELMWOOD trial demonstrated that **Elafibranor was well tolerated** in patients with PSC and showed **significant biochemical improvements** over 12 weeks compared to placebo. Key findings include: - **ALP reductions**: Elafibranor led to substantial decreases in ALP levels, with greater responses observed at the higher dose (120 mg). ALP normalization occurred only in patients receiving Elafibranor. - **ELF score improvements**: Although changes in ELF scores were observed, the reductions were more modest. - **Safety profile**: Elafibranor was generally safe, with treatment-emergent adverse events (TEAEs) comparable to placebo, and no serious TEAEs reported in the Elafibranor groups. Overall, the trial supports the potential of Elafibranor as a promising therapeutic option for PSC, with the higher dose (120 mg) showing a greater magnitude of response. Further studies are needed to confirm long-term efficacy and safety.

Diet, exercise, ALD and Liver mortality - J of Hepatology-Jan 26

The context you provided discusses the impact of diet quality (DQ) and physical activity (PA) on alcohol-related liver mortality, which is a critical aspect of alcohol-related liver disease (ALD). Although the specific article from the *Journal of Hepatology* on January 26 is not directly referenced in the context, the study described aligns closely with the themes of diet, exercise, ALD, and liver mortality. ### Key Findings Related to Diet, Exercise, and Liver Mortality in ALD 1. **Healthy Diet and Liver Mortality:** - A healthier diet, defined as being in the top quartile of the Healthy Eating Index (HEI), significantly reduces the risk of liver-related mortality among individuals with varying levels of alcohol consumption. - Specifically, diets rich in vegetables, fruits, whole grains, seafood, plant-based proteins, and unsaturated fats—and low in solid fats, alcohol, and added sugars—are protective against liver mortality. - Among heavy and binge drinkers, a healthy diet reduced liver mortality risk by up to 86% (aSHR: 0.14 for heavy drinkers) and 84% (aSHR: 0.16 for binge drinkers), respectively, compared to those with unhealthier diets. 2. **Physical Activity and Liver Mortality:** - Regular physical activity (at least 150 minutes of moderate-intensity exercise, 75 minutes of vigorous-intensity exercise, or a combination per week) is associated with a significantly lower risk of liver-related mortality. - Physically active individuals had a reduced risk of liver mortality, even among heavy drinkers (aSHR: 0.64) and binge drinkers (aSHR: 0.31). 3. **Combined Impact of Diet and Exercise:** - The combined effects of a healthy diet and regular physical activity provide substantial protective benefits against alcohol-related liver mortality. - These lifestyle factors are particularly impactful for women, who experienced greater survival benefits compared to men. 4. **Alcohol Consumption and Risk:** - Alcohol consumption, particularly heavy drinking and binge drinking, significantly increases the risk of liver-related mortality. However, the adoption of a healthy diet and regular exercise can mitigate some of this risk. ### Implications for ALD Prognosis: - For individuals with alcohol-related liver disease or at risk of alcohol-related liver mortality, adopting a healthy diet and engaging in regular physical activity can substantially improve prognosis. - These lifestyle modifications may help reduce liver inflammation, improve metabolic health, and enhance overall liver function, thereby lowering mortality risk. - The findings also highlight the importance of public health interventions to promote dietary improvements and physical activity, particularly among populations with high alcohol consumption. ### Conclusion: Healthy eating and increased physical activity are highly impactful in mitigating the prognosis of alcohol-related liver disease (ALD) and reducing liver-related mortality. These lifestyle factors provide a non-invasive, cost-effective approach to improving outcomes for individuals at risk of or suffering from ALD.